Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2 - Wikidata - wikimedia - TriplyDB

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

http://www.wikidata.org/entity/Q26798299

about

Altered protein expression pattern in colon tissue of mice upon supplementation with distinct selenium compounds.Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity Zeolite-Containing Mixture Supplementation Ameliorated Dextran Sodium Sulfate-Induced Colitis in Mice by Suppressing the Inflammatory Bowel Disease Pathway and Improving Apoptosis in Colon Mucosa.

P2860

Q30313250-871FB2D4-6273-4DC2-81EA-8EF2B202E80A Q36084796-0A1C950A-294D-45FB-9814-E3B64BFD70F1 Q42233374-0A2AE491-064A-4E29-9CB0-C8FA4C8401B5

P2860

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

http://www.wikidata.org/entity/Q26798299

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@ast

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@en

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@nl

type

label

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@ast

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@en

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@nl

prefLabel

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@ast

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@en

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@nl

P1433

Q26798299-DF27D633-DF0A-494D-A45F-7C16D0EE7017

P1476

Q26798299-46332141-FD68-4FF4-A360-0FC35D17BEAB

P2093

Q26798299-0369CE6A-5B31-41EF-B220-7E87D30333F8

Q26798299-0C79D834-8A62-4AE4-9D37-0679E9497B40

Q26798299-2EB84E69-49B5-4FD7-918B-D3E674695FEC

Q26798299-32B391C2-C777-48D1-8956-EE50588E0F3F

Q26798299-444A1E85-F998-474F-9F3D-DA47C772A84F

Q26798299-9E96E0A5-CBE5-4499-81A2-D3C9DFA41698

Q26798299-BFE92987-2FAA-40FA-8D9A-7093B74014D4

P2860

Q26798299-00AF2F64-9126-4091-B260-29936BEB1D2E

Q26798299-00D47543-69C4-49AF-AEAD-30A0450FE56A

Q26798299-02EBDDC8-09FD-4A75-AE21-391A6FD9E62C

Q26798299-079F7D76-EC0E-471E-A82A-4B2F48A6955C

Q26798299-1077AFBC-FF5A-402E-8CA7-D915E2801F34

Q26798299-11D59A8F-E7D1-45DB-BD10-1CAF5941A473

Q26798299-121B4BE0-2751-47A5-9399-354C1946148F

Q26798299-12DFD8CB-0C18-4244-822F-E9F2E8B5D843

Q26798299-138871CA-B651-4B2B-828A-15EC88CF1E7B

Q26798299-17D503C9-C0ED-4B50-B703-7FF8DB032BB0

P304

Q26798299-2E38E6B8-DD79-449A-A71B-113B16F7545F

P31

Q26798299-1C1F94CA-B768-4F2B-9323-B0CE0C4478BE

P3181

Q26798299-865AE4E7-652F-4A0D-A225-B638D071CAC6

P356

Q26798299-B4D65F13-208B-4145-81E9-5D33182F6A59

P407

Q26798299-06F26A64-9026-4947-8C17-197B96C2E41C

P433

Q26798299-904B684B-980B-4BB5-9261-8C9DDB3302BC

P478

Q26798299-827FE335-5650-4941-81C7-2EAF521465F3

P577

Q26798299-BCF71547-250F-4C4D-95B5-15336824637A

P5875

Q26798299-897D2A03-615A-4CC3-9A7C-DFFD0870F22D

P698

Q26798299-21612D2C-4E4A-4015-85E9-18F10957F4EF

P932

Q26798299-FA5732E8-C30F-4C51-ACCC-82F0D2656DD7

P3181

P356

WJG.V21.I29.8776

P1433

World Journal of Gastroenterology

P1476

Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

@en

P2093

Hiromi Kataoka

http://www.w3.org/2001/XMLSchema#string

Keiji Ozeki

http://www.w3.org/2001/XMLSchema#string

Satoshi Tanida

http://www.w3.org/2001/XMLSchema#string

Takahito Katano

http://www.w3.org/2001/XMLSchema#string

Takashi Joh

http://www.w3.org/2001/XMLSchema#string

Takeshi Kamiya

http://www.w3.org/2001/XMLSchema#string

Tsutomu Mizoshita

http://www.w3.org/2001/XMLSchema#string

P2860

Vedolizumab for induction and maintenance of remission in ulcerative colitis

Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases

Infliximab for induction and maintenance therapy for ulcerative colitis

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Annexins: linking Ca2+ signalling to membrane dynamics

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

P304

8776-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4421353

http://www.w3.org/2001/XMLSchema#string

P356

10.3748/WJG.V21.I29.8776

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280997492

http://www.w3.org/2001/XMLSchema#string

P698

26269667

http://www.w3.org/2001/XMLSchema#string

P932

4528020

http://www.w3.org/2001/XMLSchema#string